ANI's Generic L-Glutamine Oral Powder Hits Market, Targets $20.1M Annual Sales
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has launched its FDA-approved generic L-Glutamine Oral Powder, targeting $20.1 million in annual sales. This product is the first AA-rated generic version of Endari®.
July 15, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals has launched its FDA-approved generic L-Glutamine Oral Powder, expected to generate $20.1 million in annual sales. This launch marks the first AA-rated generic version of Endari®.
The launch of the FDA-approved generic L-Glutamine Oral Powder is a significant milestone for ANI Pharmaceuticals, potentially boosting its revenue by $20.1 million annually. The product's approval and market entry demonstrate the company's strong R&D capabilities and commitment to providing high-quality therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100